pamidronate has been researched along with Cherry Red Spot Myoclonus Syndrome in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Intravenous pamidronate treatment given monthly for a year was well tolerated and produced dramatic clinical effects, with reduction in bone pain and improvements in mobility, despite incomplete suppression of bone resorption as assessed by biochemical, radiographic and histological criteria." | 3.71 | The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment. ( Baker, N; Cundy, T; David, G; Hofman, P; King, A; Noble, J; Robinson, C; Sillence, D, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Robinson, C | 1 |
| Baker, N | 1 |
| Noble, J | 1 |
| King, A | 1 |
| David, G | 1 |
| Sillence, D | 1 |
| Hofman, P | 1 |
| Cundy, T | 1 |
1 other study available for pamidronate and Cherry Red Spot Myoclonus Syndrome
| Article | Year |
|---|---|
The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment.
Topics: Absorptiometry, Photon; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Bone Density; Bone Dise | 2002 |